Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Heart Diseases 3Vascular Diseases 2Small Cell Lung Carcinoma 2Leukemia, Myeloid, Acute 2Cardiovascular Diseases 2Cardiotoxicity 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metabolic Diseases 1Liver Neoplasms 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Immune-related Adverse Event 1Hematologic Neoplasms 1Heart Failure 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1

Interventions

tovorafenib 1binimetinib 1Carboplatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Noonan Syndrome 5 × Antineoplastic Agents × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡